TimesSquare Capital Management LLC Has $15.69 Million Position in CG Oncology, Inc. (NASDAQ:CGON)

TimesSquare Capital Management LLC grew its stake in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 25.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 546,904 shares of the company's stock after purchasing an additional 109,835 shares during the quarter. TimesSquare Capital Management LLC owned approximately 0.72% of CG Oncology worth $15,685,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. State Street Corp boosted its position in shares of CG Oncology by 73.0% during the third quarter. State Street Corp now owns 1,700,653 shares of the company's stock worth $64,166,000 after buying an additional 717,722 shares during the period. Point72 Asset Management L.P. boosted its position in shares of CG Oncology by 575.7% during the third quarter. Point72 Asset Management L.P. now owns 746,063 shares of the company's stock worth $28,149,000 after buying an additional 635,653 shares during the period. Geode Capital Management LLC boosted its position in shares of CG Oncology by 96.2% during the third quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company's stock worth $40,701,000 after buying an additional 528,749 shares during the period. Wellington Management Group LLP lifted its position in CG Oncology by 153.4% in the third quarter. Wellington Management Group LLP now owns 510,219 shares of the company's stock worth $19,251,000 after purchasing an additional 308,852 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in CG Oncology by 114.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 379,664 shares of the company's stock worth $14,325,000 after purchasing an additional 202,262 shares during the period. 26.56% of the stock is owned by institutional investors.

CG Oncology Price Performance

Shares of NASDAQ:CGON traded down $0.37 on Friday, reaching $27.85. 369,894 shares of the company traded hands, compared to its average volume of 411,575. CG Oncology, Inc. has a fifty-two week low of $25.77 and a fifty-two week high of $48.05. The company's 50 day moving average is $29.20 and its 200-day moving average is $33.40.

Insider Activity

In other CG Oncology news, Director Hong Fang Song sold 700,000 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $28.00, for a total transaction of $19,600,000.00. Following the sale, the director now directly owns 3,003,931 shares of the company's stock, valued at $84,110,068. The trade was a 18.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Leonard E. Post sold 1,000 shares of the business's stock in a transaction on Friday, December 6th. The shares were sold at an average price of $34.54, for a total transaction of $34,540.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 702,000 shares of company stock worth $19,664,200.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. HC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of CG Oncology in a research report on Friday, January 10th. Royal Bank of Canada restated an "outperform" rating and issued a $66.00 target price on shares of CG Oncology in a research report on Friday, December 6th. Finally, TD Cowen assumed coverage on CG Oncology in a research report on Tuesday, January 7th. They issued a "buy" rating for the company. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $65.14.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.